Affiliation:
1. National Institute for Health and Care Research Greater Manchester Patient Safety Translational Research Centre, Manchester Academic Health Science Centre University of Manchester Manchester UK
2. Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester Manchester UK
3. Centre for Mental Health and Safety, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester Manchester UK
Abstract
AbstractBackground and AimsAn apparently protective effect of opioid agonist treatment (OAT) on all‐cause and cause‐specific mortality risk has been widely reported. Non‐fatal overdose (NFO) often precedes subsequent drug‐poisoning deaths. We hypothesized that benzodiazepines, gabapentinoids, antipsychotics, antidepressants, Z‐drugs or opioids increase the NFO risk when co‐prescribed with OAT.DesignWe conducted a cohort study using the Clinical Practice Research Datalink GOLD and Aurum databases. The cohort was linked to Hospital Episode Statistics admitted patient care data (HES‐APC), neighbourhood‐ and practice‐level Index of Multiple Deprivation quintiles and mortality records from the Office for National Statistics.SettingPrimary care in England.ParticipantsWe studied patients with opioid use disorder, aged 18–64 years, who were prescribed OAT (15155 methadone and 5743 buprenorphine recipients) between Jan 1, 1998, and Dec 31, 2017.MeasurementsThe main outcome examined was NFO risk during co‐prescription of OAT with benzodiazepines, antipsychotics, gabapentinoids, antidepressants, Z‐drugs or opioids. Overdose was defined according to International Classification of Diseases codes from the HES‐APC data set. Negative binomial regression models were used to estimate weighted rate ratios (wRR) for NFO during co‐prescription of OAT and benzodiazepines, antipsychotics, gabapentinoids, antidepressants, Z‐drugs or opioids with periods of exclusive OAT usage.FindingsAmong 20 898 patients observed over 83 856 person‐years, we found an elevated overdose risk that resulted in hospital admission during co‐prescription of OAT with benzodiazepines [wRR: 1.45; 95% confidence interval (CI) = 1.26–1.67], gabapentinoids (wRR = 2.22; 95% CI = 1.77–2.79), Z‐drugs (wRR = 1.60; 95% CI = 1.31–1.96), antipsychotics (wRR = 1.85; 95% CI = 1.53–2.25) and opioids (wRR = 1.28; 95% CI = 1.02–1.60). The risk ratio for antidepressant co‐prescriptions was below unity (wRR = 0.90; 95% CI = 0.79–1.02) but this result was not statistically significant.ConclusionElevated risk of non‐fatal overdose among opioid agonist treatment recipients is associated with concurrent use of medication prescribed for other reasons.
Subject
Psychiatry and Mental health,Medicine (miscellaneous)
Reference31 articles.
1. Global patterns of opioid use and dependence: harms to populations, interventions, and future action
2. Office for National Statistics.Deaths related to drug poisoning in England and Wales: 2020 registrations.2021. Available at:https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2020. Accessed 18 Sept 2021.
3. Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group.Drug Misuse and Dependence: UK Guidelines on Clinical Management.2017. Available at:https://www.gov.uk/government/publications/drug-misuse-and-dependence-uk-guidelines-on-clinical-management. Accessed 10 Apr 2020.
4. Treatment of Opioid Dependence
5. Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis